or Try an Advanced Search...

    ETF Components for ARKG - ARK Genomic Revolution Multi-Sector ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    TWST F 3.00 8.58
    CRSP C 9.42 7.19
    RXRX F 1.27 7.13
    CDNA D 2.30 5.09
    VCYT A 1.69 4.56
    IONS F 0.96 4.40
    ADPT A 9.71 4.37
    NRIX B -0.45 4.29
    NTLA F 4.15 3.81
    NTRA B 2.65 3.75
    TXG F 1.87 3.63
    SDGR F 2.24 3.51
    BEAM F 4.66 3.46
    ARCT F 1.52 3.22
    PSNL C 0.79 2.91
    GH D 5.12 2.64
    ABSI D 2.08 2.43
    VEEV B 1.89 2.13
    PACB C 12.44 2.11
    AMGN C -0.29 1.94
    VRTX D -1.02 1.56
    ACCD F 0.95 1.42
    BFLY A 14.04 1.32
    EXAS A 1.26 1.26
    INCY A 2.71 1.25
    CERS F -3.18 1.12
    REGN F 0.64 1.12
    MRNA F 0.50 1.08
    CMPS F -0.21 1.00
    PRME C 3.87 0.92
    MASS F 10.37 0.86
    QSI F 9.59 0.73
    RPTX C 6.87 0.72
    ILMN A 3.90 0.26

    Represented by ETF Holdings

    Keywords: Biotechnology Cancer Biology Biopharmaceutical Drug Discovery Life Sciences Medicine Genomics Nasdaq 100 Molecular Biology S&P 500 Telehealth Telemedicine Acid Genetics Lab Testing Precision Medicine Blood Test Breakthrough Therapy CRISPR
    Industries: Biotechnology Diagnostics & Research Health Information Services Health Information Services Medical Devices Drug Manufacturers - Major Medical Care Facilities

    Recent News for ARK Genomic Revolution Multi-Sector ETF & its Holdings

    Date Stock Title
    Nov 2 INCY What Moved Markets This Week
    Nov 1 RXRX Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
    Nov 1 CMPS Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
    Nov 1 ILMN Stocks to watch next week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
    Nov 1 VRTX Stocks to watch: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
    Nov 1 BFLY Butterfly Network, Inc. (BFLY) Q3 2024 Earnings Call Transcript
    Nov 1 CMPS Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
    Nov 1 TXG Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
    Nov 1 ADPT November 2024's Top US Penny Stocks With Growth Potential
    Nov 1 REGN What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?
    Nov 1 NTRA Natera to Report its Third Quarter 2024 Results on November 12, 2024
    Nov 1 BFLY Butterfly Network, Inc. (BFLY) Reports Q3 Loss, Tops Revenue Estimates
    Nov 1 GH Guardant Health to Participate in Upcoming Investor Conferences
    Nov 1 BFLY Butterfly Network GAAP EPS of -$0.08 beats by $0.01, revenue of $20.6M beats by $1.59M
    Nov 1 BFLY Butterfly Network Reports Third Quarter 2024 Financial Results
    Nov 1 REGN Regeneron Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
    Nov 1 CERS Cerus Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Nov 1 AMGN Amgen Third Quarter 2024 Earnings: EPS Beats Expectations
    Nov 1 REGN Regeneron: Investors In Panic Mode On Increased Eylea Fears
    Nov 1 REGN Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
    Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
    Exchange Traded Fund ETF Biotechnology Stem Cell Genomics Bioinformatics
    Back to the Main ARKG Page...